Evidence map›Paper›PMID 40305478›Full record

ArticleNeuro-oncology2025

The T-cell receptor repertoire: A window into pediatric brain tumor immunity.

Takahide Nejo, Robert M Prins, Hideho Okada

Abstract read
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Takahide NejoDepartment of Neurological Surgery, University of California, San Francisco, California, USA.ORCID 0000-0002-9191-8823
Robert M PrinsParker Institute for Cancer Immunotherapy, San Francisco, California, USA.ORCID 0000-0002-6282-6583
Hideho OkadaHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA.ORCID 0000-0003-0076-9920

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Preclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0M
NCI NIH HHS 1R01CA267726NCI NIH HHS P50 CA211015NCI NIH HHS P50CA211015NCI NIH HHS R35NS105068NINDS NIH HHS R35 NS105068
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40305478
PMCPMC12526131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.